GDC-0084 Emerging Drug Insight

“GDC-0084 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about GDC-0084 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the GDC-0084 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the GDC-0084 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the GDC-0084 market forecast analysis for GBM in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

Paxalisib (GDC-0084) inhibits the PI3K pathway, which is thought to be critical to developing certain tumors.  GDC-0084 is currently involved in five clinical trials examining the drug in various forms of brain cancer, including GBM, DIPG, and breast cancer brain metastases (BCBM), and the lead indication for paxalisib is GBM. The drug candidate is currently in an adaptive Phase II/III pivotal study for potential registration called GBM AGILE. The Global Coalition sponsors this study for adaptive research, a US-based not-for-profit organization, and uses cutting-edge statistical techniques to accelerate the development of new therapies.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the GDC-0084 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on GDC-0084 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the GDC-0084 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around GDC-0084.
• The report contains forecasted sales of GDC-0084 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for GDC-0084 in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GDC-0084 Analytical Perspective by DelveInsight

• In-depth GDC-0084 Market Assessment

This report provides a detailed market assessment of GDC-0084 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• GDC-0084 Clinical Assessment

The report provides the clinical trials information of GDC-0084 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GDC-0084 dominance.
• Other emerging products for GBM are expected to give tough market competition to GDC-0084 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GDC-0084 in GBM.
• Our in-depth analysis of the forecasted sales data of GDC-0084 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GDC-0084 in GBM.

Key Questions

• What is the product type, route of administration and mechanism of action of GDC-0084?
• What is the clinical trial status of the study related to GDC-0084 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GDC-0084 development?
• What are the key designations that have been granted to GDC-0084 for GBM?
• What is the forecasted market scenario of GDC-0084 for GBM?
• What are the forecasted sales of GDC-0084 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to GDC-0084 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?